Disease-modifying drugs for multiple sclerosis and subsequent health service use.

ABSTRACT:

Objective

We assessed the relationship between the multiple sclerosis (MS) disease-modifying drugs (DMDs) and healthcare use.

Methods

Persons with MS (aged ⩾18 years) were identified using linked population-based health administrative data in four Canadian provinces and were followed from the most recent of their first MS/demyelinating event or 1 January 1996 until the earliest of death, emigration, or study end (31 December 2017 or 31 March 2018). Prescription records captured DMD exposure, examined as any DMD, then by generation (first-generation (the injectables) or second-generation (orals/infusions)) and individual DMD. The associations with subsequent all-cause hospitalizations and physician visits were examined using proportional means model and negative binomial regr

SUBMITTER: Ng HS 

PROVIDER: S-EPMC8958569 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature